Conjugation of human topoisomerase 2α with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: Cell cycle stage and chromosome domain specificity

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2409-2418

  Agostinho, Marta ^a   Santos, Vera ^a   Ferreira, Fernando ^a,b   Costa, Rafael ^a   Cardoso, Joana ^a   Pinheiro, Inês ^a   Rino, José ^a   Jaffray, Ellis ^c   Hay, Ronald T ^c   Ferreira, João ^a,d  

^a INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES   (Portugal)

^b FACULDADE DE MEDICINA VETERINÁRIA   (Portugal)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2ALPHA; DNA TOPOISOMERASE INHIBITOR; ETOPOSIDE; PROTEIN INHIBITOR OF ACTIVATED STAT; RAZOXANE; SUMO 1 PROTEIN; SUMO 2 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANAPHASE; ARTICLE; CELL CYCLE; CENTROMERE; CHROMATID; CHROMOSOME; CONTROLLED STUDY; CYTOLOGY; DRUG EFFICACY; DRUG RESPONSE; GENE TARGETING; HUMAN; HUMAN CELL; INTERPHASE; METAPHASE; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

ANTINEOPLASTIC AGENTS; CATALYSIS; CELL CYCLE; CHROMATIN; CHROMOSOMES, HUMAN; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; ENZYME INHIBITORS; ETOPOSIDE; HELA CELLS; HUMANS; INTERPHASE; MITOSIS; PROTEIN INHIBITORS OF ACTIVATED STAT; RAZOXANE; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS;

EID: 42049102803     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2092     Document Type: Article

References (40)

1. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
2. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
3. Porter AC, Farr CJ. Topoisomerase II: untangling its contribution at the centromere. Chromosome Res 2004;12:569-83.
4. Wang JC. DNAtopoisome rases. Annu Rev Biochem 1996;65:635-92.
5. Austin CA, Marsh KL. Eukaryotic DNA topoisomerase IIβ. BioEssays 1998;20:215-26.
6. Ju BG, Lunyak VV, Perissi V, et al. A topoisomerase IIβ-mediated dsDNA break required for regulated transcription. Science 2006;312:1798-802.
7. Mondal N, Parvin JD. DNA topoisomerase IIα is required for RNA polymerase II transcription on chromatin templates. Nature 2001;413:435-8.
8. Lis JT, Kraus WL. Promoter cleavage: a topoIIβ and PARP-1 collaboration. Cell 2006;125:1225-7.
9. Chang CJ, Goulding S, Earnshaw WC, Carmena M. RNAi analysis reveals an unexpected role for topoisomerase II in chromosome arm congression to a metaphase plate. J Cell Sci 2003;116:4715-26.
10. Carpenter AJ, Porter AC. Construction, characterization, and complementation of a conditional-lethal DNA topoisomerase IIα mutant human cell line. Mol Biol Cell 2004;15:5700-11.
11. Hay RT. SUMO: a history of modification. Mol Cell 2005;18:1-12.
12. Bossis G, Melchior F. SUMO: regulating the regulator. Cell Div 2006;1:13.
13. Isik S, Sano K, Tsutsui K, et al. The SUMO pathway is required for selective degradation of DNA topoisomerase IIβ induced by a catalytic inhibitor ICRF-193([1]). FEBS Lett 2003;546:374-8.
14. Mao Y, Desai SD, Liu LF. SUMO-1 conjugation to human DNA topoisomerase II isozymes. J Biol Chem 2000;275:26066-73.
15. Bachant J, Alcasabas A, Blat Y, Kleckner N, Elledge SJ. The SUMO-1 isopeptidase Smt4 is linked to centromeric cohesion through SUMO-1 modification of DNA topoisomerase II. Mol Cell 2002;9:1169-82.
16. Azuma Y, Arnaoutov A, Dasso M. SUMO-2/3 regulates topoisomerase II in mitosis. J Cell Biol 2003;163:477-87.
17. Azuma Y, Arnaoutov A, Anan T, Dasso M. PIASy mediates SUMO-2 conjugation of topoisomerase-II on mitotic chromosomes. EMBO J 2005;24:2172-82.
18. Nacerddine K, Lehembre F, Bhaumik M, et al. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice. Dev Cell 2005;9:769-79.
19. Diaz-Martinez LA, Gimenez-Abian JF, Azuma Y, et al. PIASγ is required for faithful chromosome segregation in human cells. PLoS ONE 2006;1:e53.
20. Agostinho M, Rino J, Braga J, Ferreira F, Steffensen S, Ferreira J. Human topoisomerase IIα: targeting to subchromosomal sites of activity during interphase and mitosis. Mol Biol Cell 2004;15:2388-400.
21. Vertegaal AC, Ogg SC, Jaffray E, et al. A proteomic study of SUMO-2 target proteins. J Biol Chem 2004;279:33791-8.
22. Girdwood D, Bumpass D, Vaughan OA, et al. P300 transcriptional repression is mediated by SUMO modification. Mol Cell 2003;11:1043-54.
23. Jaffray EG, Hay RT. Detection of modification by ubiquitin-like proteins. Methods 2006;38:35-8.
24. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997;272:24159-64.
25. Takahashi Y, Yong-Gonzalez V, Kikuchi Y, Strunnikov A. SIZ1/SIZ2 control of chromosome transmission fidelity is mediated by the sumoylation of topoisomerase II. Genetics 2006;172:783-94.
26. Ayaydin F, Dasso M. Distinct in vivo dynamics of vertebrate SUMO paralogues. Mol Biol Cell 2004;15:5208-18.
27. Maeshima K, Laemmli UK. A two-step scaffolding model for mitotic chromosome assembly. Dev Cell 2003;4:467-80.
28. Gassmann R, Vagnarelli P, Hudson D, Earnshaw WC. Mitotic chromosome formation and the condensin paradox. Exp Cell Res 2004;296:35-42.
29. Nitiss JL, Pourquier P, Pommier Y. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res 1997;57:4564-9.
30. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:139-54.
31. Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem 1998;273:17643-50.
32. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000;64:221-53.
33. Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol 2001;41:53-77.
34. Gorbsky GJ. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis (3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane). Cancer Res 1994;54:1042-8.
35. Ihara M, Yamamoto H, Kikuchi A. SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-dependent activation of Tcf-4. Mol Cell Biol 2005;25:3506-18.
36. Watts FZ. The role of SUMO in chromosome segregation. Chromosoma 2007;116:15-20.
37. Laemmli UK, Kas E, Poljak L, Adachi Y. Scaffold-associated regions: cis-acting determinants of chromatin structural loops and functional domains. Curr Opin Genet Dev 1992;2:275-85.
38. Earnshaw WC, Halligan B, Cooke CA, Heck MM, Liu LF. Topoisomerase II is a structural component of mitotic chromosome scaffolds. J Cell Biol 1985;100:1706-15.
39. Warburton PE, Earnshaw WC. Untangling the role of DNA topoisomerase II in mitotic chromosome structure and function. BioEssays 1997;19:97-9.
40. Meyer KN, Kjeldsen E, Straub T, et al. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities. J Cell Biol 1997;136:775-88.